Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors.

Lei Zhao, Mingya Zhang, Jiafu Zhou, Xinglong Jia, Xiaotong Liang, Minjia Tan, Jun-Yu Xu

Abstract read

In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lei ZhaoTranslational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, and Cancer Center, School of Medicine, Tongji University, Shanghai 200434, China.

Mingya ZhangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Jiafu ZhouZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400, China.

Xinglong JiaState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Xiaotong LiangZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400, China.

Minjia TanTranslational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, and Cancer Center, School of Medicine, Tongji University, Shanghai 200434, China.ORCID https://orcid.org/0000-0002-6784-9653

Jun-Yu XuZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400, China.ORCID https://orcid.org/0000-0002-1403-9200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.

Indexed as

acetylomicsdrug combinationkinase inhibitorphosphoproteomicsPTM crosstalk

Identifiers

PMID40969873

DOI10.1021/acsptsci.5c00398

PMCPMC12441852

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.